Sino Biopharmaceutical Limited
SBHMY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -1.19 | -0.34 | 0.01 |
| FCF Yield | 9.95% | 5.58% | 6.09% | 3.99% |
| EV / EBITDA | 8.63 | 11.64 | 11.98 | 4.50 |
| Quality | ||||
| ROIC | 10.39% | 9.45% | 9.02% | 8.77% |
| Gross Margin | 81.51% | 80.95% | 82.76% | 80.15% |
| Cash Conversion Ratio | 0.95 | 1.02 | 1.08 | 0.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.51% | -0.83% | 3.25% | 3.49% |
| Free Cash Flow Growth | 19.69% | -4.33% | 31.31% | 0.18% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | 0.45 | 0.80 | 0.13 |
| Interest Coverage | 20.79 | 11.68 | 13.01 | 16.46 |
| Efficiency | ||||
| Inventory Turnover | 2.25 | 2.50 | 2.49 | 2.75 |
| Cash Conversion Cycle | 123.28 | 112.22 | 93.15 | 68.02 |